4N0Y

Structure of the Hepatitis C Envelope Glycoprotein E1 antigenic region 314-324 bound to the cross-neutralizing antibody IGH526

4N0Y の概要

• エントリーDOI: 10.2210/pdb4n0y/pdb
• 分子名称: IGH526 Heavy Chain, IGH526 Light Chain, HCV E1 peptide, ... (6 entities in total)
• 機能のキーワード: immunoglobulin fold, amidated c-terminus, immune system
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 49462.46

構造登録者

Kong, L.,Wilson, I.A. (登録日: 2013-10-02, 公開日: 2015-04-01, 最終更新日: 2024-11-27)

主引用文献

Kong, L.,Kadam, R.U.,Giang, E.,Ruwona, T.B.,Nieusma, T.,Culhane, J.C.,Stanfield, R.L.,Dawson, P.E.,Wilson, I.A.,Law, M.
Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.
J.Mol.Biol., 427:2617-2628, 2015

PubMed Abstract: Hepatitis C virus (HCV) is a positive-strand RNA virus within the Flaviviridae family. The viral "spike" of HCV is formed by two envelope glycoproteins, E1 and E2, which together mediate viral entry by engaging host receptors and undergoing conformational changes to facilitate membrane fusion. While E2 can be readily produced in the absence of E1, E1 cannot be expressed without E2 and few reagents, including monoclonal antibodies (mAbs), are available for study of this essential HCV glycoprotein. A human mAb to E1, IGH526, was previously reported to cross-neutralize different HCV isolates, and therefore, we sought to further characterize the IGH526 neutralizing epitope to obtain information for vaccine design. We found that mAb IGH526 bound to a discontinuous epitope, but with a major component corresponding to E1 residues 314-324. The crystal structure of IGH526 Fab with this E1 glycopeptide at 1.75Å resolution revealed that the antibody binds to one face of an α-helical peptide. Single mutations on the helix substantially lowered IGH526 binding but did not affect neutralization, indicating either that multiple mutations are required or that additional regions are recognized by the antibody in the context of the membrane-associated envelope oligomer. Molecular dynamics simulations indicate that the free peptide is flexible in solution, suggesting that it requires stabilization for use as a candidate vaccine immunogen.

PubMed: 26135247
DOI: 10.1016/j.jmb.2015.06.012

実験手法

X-RAY DIFFRACTION (1.749 Å)